Comprehensive dosimetric planning comparison for early-stage, non-small cell lung cancer with SABR: fixed-beam IMRT versus VMAT versus TomoTherapy.
Volumetric-modulated arc therapy (VMAT) is emerging as a leading technology in treating early-stage, non-small cell lung cancer (NSCLC) with stereotactic ablative radiotherapy (SABR). However, two other modalities capable of deliver-ing intensity-modulated radiation therapy (IMRT) include fixed-beam and helical TomoTherapy (HT). This study aims to provide an extensive dosimetric compari-son among these various IMRT techniques for treating early-stage NSCLC with SABR. Ten early-stage NSCLC patients were retrospectively optimized using three fixed-beam techniques via nine to eleven beams (high and low modulation step-and-shoot (SS), and sliding window (SW)), two VMAT techniques via two partial arcs (SmartArc (SA) and RapidArc (RA)), and three HT techniques via three different fan beam widths (1 cm, 2.5 cm, and 5 cm) for 80 plans total. Fixed-beam and VMAT plans were generated using flattening filter-free beams. SS and SA, HT treatment plans, and SW and RA were optimized using Pinnacle v9.1, Tomoplan v.3.1.1, and Eclipse (Acuros XB v11.3 algorithm), respectively. Dose-volume histogram statistics, dose conformality, and treatment delivery efficiency were analyzed. VMAT treatment plans achieved significantly lower values for contralat-eral lung V5Gy (p ≤ 0.05) compared to the HT plans, and significantly lower mean lung dose (p < 0.006) compared to HT 5 cm treatment plans. In the comparison between the VMAT techniques, a significant reduction in the total monitor units (p = 0.05) was found in the SA plans, while a significant decrease was observed in the dose falloff parameter, D2cm, (p = 0.05), for the RA treatments. The maximum cord dose was significantly reduced (p = 0.017) in grouped RA&SA plans com-pared to SS. Estimated treatment time was significantly higher for HT and fixed-beam plans compared to RA&SA (p < 0.001). Although, a significant difference was not observed in the RA vs. SA (p = 0.393). RA&SA outperformed HT in all parameters measured. Despite an increase in dose to the heart and bronchus, this study demonstrates that VMAT is dosimetrically advantageous in treating early-stage NSCLC with SABR compared to fixed-beam, while providing significantly shorter treatment times.
Western University; London Regional Cancer Program. ilma.xhaferllari@lhsc.on.ca.
Ilma
I
Xhaferllari
Omar
O
El-Sherif
Stewart
S
Gaede
D000465:Algorithms; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000601:surgery*; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D058958:Organs at Risk / Q000528:radiation effects*; D018579:Patient Selection; D016634:Radiosurgery / Q000379:methods*; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods*; D050397:Radiotherapy, Intensity-Modulated / Q000379:methods*; D012189:Retrospective Studies
Oncol Lett. 2013 Mar;5(3):840-844
23426072
J Appl Clin Med Phys. 2015 Mar 08;16(2):4964
26103170
Med Phys. 2008 Jan;35(1):310-7
18293586
J Appl Clin Med Phys. 2012 May 10;13(3):3751
22584174
Acta Oncol. 2006;45(7):890-6
16982555
Med Phys. 1993 Nov-Dec;20(6):1709-19
8309444
Med Phys. 2014 Mar;41(3):031709
24593713
Med Phys. 2014 Aug;41(8):081715
25086525
Phys Med Biol. 2006 Jul 7;51(13):R427-53
16790916
Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):344-9
19765913
J Med Phys. 2013 Oct;38(4):165-72
24672150
BMC Cancer. 2012 Jul 23;12:305
22823994
Med Phys. 2004 Oct;31(10):2899-911
15543799
CA Cancer J Clin. 2015 Mar;65(2):87-108
25651787
Technol Cancer Res Treat. 2015 Feb;14 (1):49-60
24325136
Radiat Oncol. 2009 Jan 12;4:1
19138400
Technol Cancer Res Treat. 2015 Aug;14 (4):411-8
25261069
Acta Oncol. 1994;33(6):677-83
7946448
Acta Oncol. 2006;45(7):978-88
16982567
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1241-56
15519797
Chest. 2005 Sep;128(3):1461-7
16162744
Med Phys. 2010 Aug;37(8):4078-101
20879569
Radiother Oncol. 2013 Oct;109(1):95-9
24183862
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):333-42
16414369
Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):603-11
25052562
Radiother Oncol. 2010 May;95(2):153-7
20116115
Radiat Oncol. 2011 Sep 12;6:113
21910868
J Appl Clin Med Phys. 2013 Jul 08;14 (4):4065
23835374
Behav Res Methods. 2007 May;39(2):175-91
17695343